BioMarin Pharmaceutical Inc. Files 8-K on Shareholder Votes
Ticker: BMRN · Form: 8-K · Filed: May 24, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: BMRN
TL;DR
BioMarin filed an 8-K on May 24th about shareholder votes from May 21st.
AI Summary
BioMarin Pharmaceutical Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of security holders on May 21, 2024. The filing details the company's principal executive offices located at 770 Lindaro Street, San Rafael, California, 94901.
Why It Matters
This filing provides official notification of corporate actions and decisions made by BioMarin's security holders, which can impact the company's governance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating any immediate financial distress or significant operational changes.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
- May 24, 2024 (date) — Date of Report
- 770 Lindaro Street, San Rafael, California, 94901 (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of BioMarin's security holders on May 21, 2024?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on matters submitted to a vote of security holders, as indicated by the 'Submission of Matters to a Vote of Security Holders' item information.
Where are BioMarin Pharmaceutical Inc.'s principal executive offices located?
BioMarin Pharmaceutical Inc.'s principal executive offices are located at 770 Lindaro Street, San Rafael, California, 94901.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 24, 2024.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-05-24 16:02:04
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BMRN The Nasdaq Global Se
Filing Documents
- d95239d8k.htm (8-K) — 38KB
- 0001193125-24-147013.txt ( ) — 155KB
- bmrn-20240521.xsd (EX-101.SCH) — 3KB
- bmrn-20240521_lab.xml (EX-101.LAB) — 17KB
- bmrn-20240521_pre.xml (EX-101.PRE) — 11KB
- d95239d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: May 24, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer